3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Conditions
Breast Neoplasms
11
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
HER2-positive Breast Cancer
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Meningeal Carcinomatosis
1
Hemangiosarcoma
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Dexamethasone
87
daratumumab
49
Lenalidomide
49
pomalidomide
33
Bortezomib
32
Cyclophosphamide
31
carfilzomib
25
Calcium Dobesilate
21
talquetamab
19
fludarabine
18
isatuximab
16
iberdomide
16
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Biopsy
14
selinexor
12
Melphalan
11
belantamab mafodotin
10
dexamethasone acetate
9
dexamethasone 21-phosphate
8
elotuzumab
7
auricularum
7
venetoclax
6
tocilizumab
5
fludarabine phosphate
5
X-Rays
5
Blood Specimen Collection
5
ruxolitinib
4
Methylprednisolone
4
Injections
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Multiple Myeloma
×
tucatinib
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled